Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biotechnology company with ...

About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of ...

PDS Biotechnology ( ($PDSB) ) has shared an update. On June 2, 2025, PDS Biotechnology Corporation announced the publication of three Versamune® ...

Poster to highlight long-term therapeutic benefits of THIO sequenced with cemiplimab beyond treatment cessation CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA ...

Today announced new data from the Phase I/II GOBLET clinical trial in a poster presentation at the 2025 American Society of ...

The second abstract accepted for poster presentation contains new pre-clinical data for the next candidate in the IO Biotech pipeline, IO112, which targets Arginase 1. Times: Poster hall ...

Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC) MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a ...

For more information, please visit the EACR 2025 website. Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune ...

MAIA Biotechnology, Inc. (NYSE American ... efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of ...

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline ...